Skip to content
Search

Latest Stories

Distressed pharmacy sales to increase in 2024, property adviser Christie & Co predicts

Last year, 45 per cent of pharmacies were sold to first-time buyers and 55 per cent to independent contractors and regional multiple operators through the broker 

Specialist business property adviser, Christie & Co has predicted that 2024 will be a big year for pharmacy sector in the UK, thanks to the introduction of the £645 million investment and the Pharmacy First scheme.


However, an increase in distressed pharmacy sales is also expected this year, the broker stated in its Business Outlook 2024 report, published on Thursday (12 January).

The report reflects on the transactional activity and challenges of 2023 and forecasts what this year might bring across the industries in which the broker operates in, including the pharmacy sector.

Christie & Co said they saw a strong transactional activity across the pharmacy sector in 2023, despite ongoing operational challenges, and offers were accepted, on average, at 2.5 per cent above asking price.

They made more sales agreement over the year, but completion volumes declined by 15 per cent, largely due to ongoing delays in the change of ownership process, the report revealed.

Last year, 45 per cent of pharmacies were sold to first-time buyers and 55 per cent to independent contractors and regional multiple operators through the broker.

A noticeable rise in the number of distressed pharmacy sales was seen in the second half of the year, driven by the continued pressures faced by contractors, and this trend is expected to continue throughout 2024, according to the property adviser.

Tony Evans, Head of Pharmacy at Christie & Co, commented: “2024 will no doubt be a big year for pharmacy. The introduction of the £645 million additional services funding and the successful rollout of the Pharmacy First style minor ailments scheme will no doubt provide much-needed additional income in offering some respite to contractors.

“However, the key driver to the future viability of the sector will be the successful outcome of the wider funding agreement to replace that previously agreed as part of the Community Pharmacy Contractual Framework’s 5-year deal in 2019.”

Also, it is predicted that there will be continued interest from existing operators, particularly for defensive purchases, and opportunities for investors and those with finance who are looking to enter the pharmacy market.

Pharmacies remained a preferred lending sector, with significant borrowing opportunities, according to Christie & Co’s Business Outlook 2024 report.

LloydsPharmacy disposals led to a surge in pharmacy transactions in 2023, putting pressure on lenders, valuers, solicitors, and NHS England, causing inevitable delays in the sales process, it stated.

Furthermore, the company’s annual sentiment survey revealed that while 46 per cent of pharmacy professionals are positive about 2024, It’s either neutral or negative about what’s to come for the rest 55 per cent.

About 85 per cent of the respondents (pharmacy professionals across the country) said they are planning to either buy or sell this year.

More For You

Walgreens Boots Alliance acquired by Sycamore in deal

Walgreens Boots Alliancehas entered into “a definitive agreement” to be acquired by Sycamore Partners

Gettyimages

Walgreens Boots Alliance acquired by Sycamore in £18.3 billion deal

Walgreens Boots Alliance(WBA) has entered into “a definitive agreement” to be acquired by Sycamore Partners, a private equity firm specializing in retail, consumer and distribution-related investments.

“The total value of the transaction represents up to $23.7 billion (£18.3 billion),” the company announced late last night (6).

Keep ReadingShow less
Professor Sir Stephen Powis at a press briefing

Professor Sir Stephen Powis, was appointed national medical director of NHS England in 2018

NHS

NHS England’s top doctor to step down following Amanda Pritchard’s resignation

Just a week after NHS England chief executive Amanda Pritchard announced her resignation, the organisation’s national medical director, Professor Sir Stephen Powis, has confirmed he will step down this summer after more than seven years in the role.

In a statement released on Thursday, Professor Powis revealed that he had informed Pritchard of his intention to leave in a letter back in January.

Keep ReadingShow less
PDA calls on GP practices to use funding boost to improve job security for pharmacists

Now, it is time to focus on the community pharmacy contract

gettyimages

PDA urges GP practices to ensure funding boost supports employed pharmacists

The Pharmacists' Defence Association (PDA) has called on GP practicesto ensure that all healthcare professionals they employ, including pharmacists, benefit from the 7.2% funding boost they received under a newly agreed contract.

GP employers are encouraged to improve “job security, pay and conditions” for employees with this increased funding.

Keep ReadingShow less
Fourth Shift: Investment in Innovative Medicines Crucial for NHS 10-Year Plan Success

Medicines should be viewed as an investment rather than a cost

gettyimages

ABPI wants to see a ‘fourth shift’ in NHS 10-Year Health Plan


The Association of the British Pharmaceutical Industry (ABPI) has called on the government to increase investment in innovative medicines and vaccines, describing it as a crucial “fourth shift” necessary to ensure the NHS is fit for the future.

Keep ReadingShow less
Lawrence Tallon named new MHRA chief executive

Lawrence Tallon

Photo credit: Sciana Network

Lawrence Tallon named new MHRA chief executive

Lawrence Tallon has been appointed as the new chief executive officer of the Medicines and Healthcare products Regulatory Agency (MHRA), effective 1 April 2025.

He will succeed Dame June Raine DBE, who is retiring after leading the agency since 2019.

Keep ReadingShow less